No abstract

BioBacta

In the Reduction of Endpoints in NIDDM (noninsulin-dependent diabetes mellitus) with the Angiotensin II Antagonist Losartan study (RENAAL study), Losartan reduced the risk of the doubling of serum creatinine concentration by 25% and of end stage renal disease (ESRD) by 28%. Methods: 40 albino rats were enrolled in this study, and they were divided into four main groups, each group 10 rats. Where, group I, serves as a control, and group II was treated with Gentamicin 80mg/kg. The group III was treated with Losartan. While, group IV was treated with Losartan and Gentamicin. Results: showed that Losartan has statistically significant nephro-protective effects. Their nephro-protective effects were assessed by:-1histopathological studies. 2-Measuring serum levels of BUN, and, creatinnine. Conclusions: Losartan has renal-protective effects.

Background: Anthracycline-induced cardiotoxicity is the most common constraint of its use in the treatment of various types of cancer. This study aimed to investigate the benefits of adding L-carnitine and silymarin compared to anthracycline chemotherapy alone in patients with cancer.Methods: 83 patients were recruited from the Clinical Oncology Department, Tanta University, Egypt, and prospectively randomized to receive their anthracycline-containing therapeutic regimen, control group (n¼33), anthracycline plus L-carnitine, Lcarnitine group (n¼25), or anthracycline plus silymarin, silymarin group (n¼ 25). Blood samples were collected at begging and after 6 months to measure LDH, CK-MB, cTn I, Anticardiolipin IgG, Fe, ferritin, and TIBC, and % of saturation. % EF was documented. Data were statistically analyzed by ANOVA and paired t-test. P <0.05 was statistically significant. Results:The obtained data suggested that adding L-carnitine to anthracycline chemotherapy had a significant beneficial effect on %EF (p¼0.003), anticardiolipin IgG (P¼0.000), ferritin (P¼0.000) , and TIBC(P¼0.011) , and that adding silymarin to anthracycline chemotherapy had a significantly beneficial effect on anticardiolipin IgG (P¼0.000), iron (p¼0.001),ferritin (p¼ 0.000), TIBC (p¼0.007) , and % saturation (p¼0.001) silymarin group showed a significant decrease in iron profile compared to the L-carnitine group, supporting the hypothesis of silymarin iron chelating activity. Conclusions:The co-administration of L-carnitine or silymarin with anthracyclinecontaining chemotherapy represents a new therapeutic strategy, especially silymarin, for better control of anthracycline-induced cardiotoxicity, as silymarin resulted in more beneficial effects on iron profile compared to anthracycline alone and anthracycline with L-carnitine.Legal entity responsible for the study: The authors.

Background: Direct-acting anti-viral drugs (DAAs) have become widely used for cirrhotic patients with hepatitis C infection. Virological responses are excellent with SVR rate in > 90% of cirrhotic patients. The association between the use of DAAs and the development of hepatocellular carcinoma (HCC) is debatable. Aim of the work: investigate the incidence of HCC and characteristics of tumors after DAAs therapy. Patients and methods:A prospective study of a cirrhotic patient with chronic hepatitis c virus who received 12 weeks of DAAs therapy (sofosbuvir, daclatasivir) in Mansoura specialized medical hospital and followed up for 6 months post-treatment. Untreated cirrhotic patients with hepatitis C infection for comparison.Results: amongst (27/30) 90% of patients achieved sustained virological response 12 weeks post-treatment there were 3/30 (10%) not responded, and 7/30 from treated patients vs 11/30 untreated patients had de novo HCC. Conclusion:DAAs reduced the incidence of HCC but with no significant difference with the untreated patient (refuse treatment) after six months, however, the pattern of tumor characteristics is very aggressive in the treated patient.